Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 190 participants.
Also called NCT02786979
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 190 participants
- Sponsor
- Registry
-
NCT02786979
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Terminated
Technical summary
Registry record NCT02786979. Randomized; no masking; primary purpose prevention. Start 2010-07 (registry gives no type); primary completion 2013-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Beraprost
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Astellas Pharma Inc
Record details
- Record id
cardio:ct-nct02786979- Content hash
02c2d9342b4c76b4d3eceb9b2de3569987b6b1b408afbb09aa0d6277054f5de8